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A. Hazenberg1,2,3*, H.A.M. Kerstjens1,3 and P.J. Wijkstra1,2,3In the majority of studies, no Data and Safety Monitor-
ing Board (DSMB) is either needed or instituted. We re-
port an investigator initiated study where we should
have done this earlier than we did and discuss the les-
sons we learned.
The EOLUS study was a single center, randomized
controlled trial of the initiation of chronic home mech-
anical ventilation (HMV) at home. Typical indications
for HMV are neuromuscular diseases such as amyo-
trophic lateral sclerosis (ALS) and Duchenne's disease
next to thoracic cage deformities. The study was set up
to investigate whether the initiation of HMV at home
with the help of telemonitoring was not inferior to our
usual in hospital start. The primary outcome measure
was change in arterial carbon dioxide pressure from
baseline to 6 months, for which we calculated a neces-
sary sample size of 52 evaluable patients. The study was
performed by an experienced nurse practitioner, as part
of a PhD project. Weekly informal supervision was done
by a senior pulmonologist and monthly progress meet-
ings were held in a larger group. At these meetings, in-
clusion, lists of those excluded, and dropouts with their
reasons and all deaths were discussed and minutes were
always made and distributed. At four occasions over the
first 14 months, a death of a patient, all with ALS, was
discussed. The number of deaths occurring in this se-
verely ill patients group, nor the circumstances were
deemed remarkable. After the inclusion of 33 patients,
all events were totaled and presented as such. We were
shocked to realize that all 4 patients had died in the
home group and none in the hospital group. The study
was immediately put on hold and we reported this to
the medical ethics committee. The ethics committee* Correspondence: a.hazenberg@umcg.nl
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ent view from experts not involved in the study, includ-
ing a statistical analysis. The conclusion of the expert
group was that the four patients had died due to the
progression of their ALS, without an identifiable link to
the intervention. They reported no lack of effectiveness
in the survivors nor safety problems. The total number
of deaths was deemed within the expected rates, but
non-normally distributed. The ethics committee ac-
cepted the interpretation of the expert group, and de-
cided to restart the study, with the requirement to
institute a DSMB. All future severe adverse events were
to be presented to the ethics committee immediately, as
were the monthly progress reports of the DSMB.
The study was subsequently finished as planned, with
77 patients randomized of which 30 with ALS. At the
end, 5 patients in the home care and 2 patients in the
hospital group had died, all with ALS. The hypothesis of
non-inferiority of HMV institution at home with the
help of telemonitoring was endorsed [1].
What did we learn? Most of all we came to fully
realize that doing any study in patient groups with a
high a priori risk of serious adverse events and especially
of deaths, a DSMB with clear pre-set guidelines, meeting
frequencies, minutes, and reporting lines to the ethics
committee should be in place. In our group, in investiga-
tor initiated studies, we had no rulings in place to see to
the institution of a DSMB. We now firmly believe such a
DSMB should be operational in all studies with high risk
interventions. That is already frequently the case in long
running pharmacy sponsored studies, and slightly less
frequently in device company sponsored studies; investi-
gator initiated studies are probably the biggest omission.
The second lesson we learned is that we should have
been keen on seeing at each meeting summary tables of
all events having occurred. We did discuss all deaths,
but became aware of the bigger, aggregate picture later
than we should have.
The DSMB consisted of a clinician expert in the field
of chronic ventilation, a statistician and a clinical experttral. This is an Open Access article distributed under the terms of the Creative
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out any involvement in the conduct of the study. The
DSMB evaluated the progress of the trial every four
months and if necessary earlier depending on the monthly
reports.
In conclusion we believe that it is of great importance
that a DSMB is involved in clinical trials not only with
high risk interventions but also with high a priori risk of
death due to disease under study. If the DSMB had been
installed from the start of our study there would have
been no reason to put the study on hold. Nevertheless,
we learned greatly from the events and nowadays it is
mandatory in our department that clinical trials with
high risk of death by the intervention or the disease,
must have an actively functioning DSMB.
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